openPR Logo

Press Releases from Greystone Research Associates (106 total)

Injectable Drug Delivery Evolving Rapidly as Protein Drugs for Chronic Condition …

(Amherst, NH) – As pharmaceutical companies struggle to position their products in the direct-to-consumer marketing era, the trend toward combining functionality and packaging in drug delivery systems is growing. Innovative drug delivery systems allow pharmaceutical companies to differentiate drug products from competitors. This is essential at a time when many patents are running out and competition among the manufacturers of generic medicines is increasing. The formulation of biologics is testing

Specialty Injectables Relying Increasingly on Autoinjectors for Delivery and Dif …

(Amherst, NH) – As injectables for chronic conditions have proliferated, devices that can be prefilled have become the primary device class for branded products. Until recently, the prefilled injection devices segment has been dominated by two major types - prefilled syringes and pen injectors, which combined for more than 80% of devices in this category on a unit basis in 2012. In the past three years, autoinjectors – pen-like devices that

Drugs Developed for Subcutaneous Injection Benefiting from the Trend to Patient …

(Amherst, NH) – As healthcare markets continue to evolve, drug developers and their supply chain partners are attempting to keep pace by addressing economic, market and therapeutic factors that increasingly revolve around how, when and where drugs are administered. This evolution is being driven by new and exciting options for patient care in the form of powerful drug therapies for treating diseases with improved outcomes and for treating diseases for

Therapeutic Antibody Drugs Being Designed for Self-Administration as Developers …

(Amherst, NH) – The administration of therapeutic antibodies is becoming an increasingly important healthcare treatment option for a growing number diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of antibody storage and administration, moving away from antibody infusion and toward injection as a

Electronics Capable of Sensing Trace VOCs and the Future of Patient Diagnostics

(Amherst, NH) – The continued evolution of microelectronics and advances in noise reduction and signal processing are paving the way toward sensing systems that can recognize trace levels of volatile organic compounds at the parts-per-billion level. By linking these devices to digital libraries and employing pattern recognition software, these devices have the potential to detect the presence of biomarkers in exhaled breath and the gaseous phase of bodily fluids to

Intradermal Drug Delivery Gaining Momentum as Technology and Benefits Converge

(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these

The Market for Therapeutic Biologicals is Evolving as Pipeline Candidates Reach …

(Amherst, NH) – Activity in the biological drug sector is set to escalate, as a growing number of drug candidates reach the market and the number of applications requesting marketing authorization for biosimilars increases to a level that will force the FDA to institute new review procedures and expand its resources. The number of new FDA-approved biologicals has averaged between four and five per year over the past decade. This

A New Generation of Glucose Sensors is Creating Options for Caregivers and their …

(Amherst, NH) – The convergence of small-scale electronics and sophisticated biocompatible product designs is giving hope for a better future to millions of diabetes patients worldwide. New glucose sensors that can measure glucose levels accurately and reliably have the capability to improve glycemic control and patient wellbeing. By utilizing new technologies for sensing glucose, this new class of sensors is creating new options for caregivers and their diabetes patients. Signal

Circulating Tumor Cells Spawning Diagnostic Tools to Guide Caregivers in Cancer …

(Amherst, NH) – Circulating tumor cells (CTCs) were first discovered more than a century ago. Because they originate from a malignant mass, they can carry useful information for clinicians with regard to the efficacy of treatments or to changes occurring within the tumor as a result of active treatment. The absence of a simple way to isolate and detect CTCs coupled with the lack of a clear understanding of the

Patient Monitors based on Wireless Body Sensor Networks Progressing as Technolog …

(Amherst, NH) – Wearable systems for continuous health monitoring are being viewed by healthcare policy decision makers as a potentially important element in improving the practice and delivery of healthcare across a broad spectrum of the population. These systems have the ability to allow caregivers and even the patient to closely monitor changes in key physiological parameters including vital signs. In its simplest form, a patient-worn Wireless Body Sensor Network (WBSN)

Self Administered Injectable Drugs to Reach $100 Billion Globally by the End of …

Growth will be impacted by Generics and New Oral APIs, according To Greystone Research Associates (Amherst, NH) – Self administered injectable drugs, a class that includes prescribed therapeutics for anti-inflammatories, antivirals, anemia, hormone replacement, fertility, osteoporosis, anticoagulants, and drugs for controlling diabetes, have grown at a CAGR of 7.7% over the past six years, as enhancements in self-injection devices have converged with improved drugs that cannot be administered orally. Based on

Disposable Drug Cartridges Changing the Injectable Therapeutics Landscape

(Amherst, NH) – As drug injection devices evolve, they are increasingly being designed to accommodate disposable drug cartridges. Because of the inherent advantages they possess, the number of devices and drug therapies that rely on prefilled drug cartridges has been growing, both within established therapeutic segments and by expanding into new injectable drug therapies. Prefilled disposable drug cartridges made their market debut as a convenient way for diabetics to administer insulin.

Despite Favorable Market Conditions Dual Chamber Device Suppliers Struggle to Sh …

(Amherst, NH) – As the number of injectable drugs supplied in powder form escalates, drug designers are increasingly incorporating reconstitution technology into their device plans. The most elegant approach to this need is the dual chamber device. A two-chamber primary package allows the patient to perform a simple procedure – for example twisting the device body – to initiate mixing of the drug power with diluent prior to initiating the

Currently at Ten Percent Market Penetration, Drug Reconstitution Systems Chasing …

(Amherst, NH) – As the number of non-small molecule drugs in the development pipeline continues to give way to more complex molecules that possess limited stability and an inability to survive the upper GI tract, the number of injectables and infusibles entering the market as solid formulations is increasing. These drugs must be reconstituted prior to use. There are currently four-hundred-forty-two FDA-approved lyophilized drug products supplied for injection and/or infusion.

Autoinjector Landscape Changing as Suppliers Re-evaluate Market Opportunities

(Amherst, NH) – Autoinjectors, which first appeared as an accessory device to aid in the administration of injectable drugs supplied in prefilled syringes, have grown to become a significant medical device market segment. As the number of drugs available in prefilled syringes as a percentage of all injectable drugs has grown, autoinjectors have experienced healthy and consistent demand, resulting in expanding competition and proliferating device product lines. Now, in response

Global Injectable Drug Market to Reach $225 Billion in 2020

(Amherst, NH) – The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing patient populations, new classes of powerful therapeutic drugs, and healthcare administration initiatives, developments that will drive the global injectable drug delivery sector to $225 billion by 2020. As new injectable drugs become available for the treatment of an

Autoimmune Disease Therapeutics Continue to Improve, but Many Challenges Remain

(Amherst, NH) – Autoimmune diseases, a group of chronic ailments that includes arthritis, psoriasis, lupus, and multiple sclerosis, afflict tens of millions of people worldwide and result in levels of morbidity that can significantly impact quality of life and longevity. They represent some of the most difficult therapeutic challenges facing the healthcare community. The refractory nature of this family of diseases is rooted in the complexities and genetic underpinnings

Evolution in Wearable Medication Systems Providing Drug Developers with New Stra …

(Amherst, NH) – Wearable drug delivery devices that adhere to the body and require no tethering to a drug reservoir or control unit are well-known to patients with Type 1 diabetes. Using this technology as a jumping point, several companies are developing devices that go beyond insulin – devices that will expose patients with a wide range of conditions to wearable drug delivery systems designed for ambulatory patient living. They

Specialty Injectable Drugs Set to Become an $85 Billion Global Market

(Amherst, NH) – The total global market for specialty injectables currently sits at $85 billion and will exceed $110 billion in 2020, according to Greystone Research Associates. The majority of growth will come from drug-device combination products. The market will continue to be driven by four therapeutic segments – autoimmune diseases, diabetes, hormone replacement, anemia and neutropenia. A fifth market – oncology - will also come into play. Oncology drugs

Engineered Drug Coatings Expanding the Therapeutic Envelope for Treating Chronic …

(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering a range of drugs for treating

Sustained Release Injectable Drugs to Exceed $17 Billion in 2020

(Amherst, NH) - For many chronic and refractory conditions, the need for frequent and continual drug injections is a therapeutic necessity, one that can be accompanied by harsh side effects and safety issues that often lead to erosion in patient compliance and therapeutic outcomes. This unmet need has placed emphasis on the value of injectable drugs specially formulated for release over an extended period of time – also known

First-Generation Patch Pumps Paving the Way for More Sophisticated Models

(Amherst, NH) – Wearable drug delivery devices that adhere to the body and require no tethering to a drug reservoir or control unit are exposing diabetic patients who rely on insulin to a new way of living with their condition. In the process, pharmaceutical and medical device companies with a stake in the diabetes market are gaining valuable insight regarding the commercial potential for this method of administration. Wearable patch pumps

Vanishing Vials and the Growth of Branding - the Brave New World of Injectable D …

(Amherst, NH) – For developers and marketers of injectable drugs, the world has changed dramatically since the start of the millennium. Once completely focused on the therapeutic formulation and content to supply/ship the drug product in glass vials, today’s injectable product managers and their drug development colleagues are faced with a growing spectrum of device, administration and packaging choices, with the knowledge that – beyond efficacy and physician detailing -

Global Injectable Drug Delivery Sector Examined in New Report

(Amherst, NH) – The rapid evolution taking place within the injectable drug delivery sector – driven by biologicals and device technology advances – continues to effect changes throughout the supply chain and syringe/injector ecosystem. New classes of injection devices have opened the way to new forms of patient self-care, introducing a growing segment of consumers to parenteral drug self-administration. The changes are impacting the various device segments in different ways

Impact of Systemic Nasal Sprays Gaining from Patient Acceptance, Diverse Pipelin …

(Amherst, NH) – Interest in nasal sprays for systemic drug delivery has increased dramatically in the last five years, driven by the need to develop new alternatives to oral delivery for protein and peptide-based drugs, and the belief that intranasal drug delivery may lead to greater drug efficacy, speed of action, safety, and patient compliance. Systemic intranasal drug delivery leverages the patient-friendly and favorable pharmacodynamics and pharmacoeconomics of intranasal administration

Delivering Hormones Transdermally Positioned to Benefit from Favorable Demograph …

(Amherst, NH) – As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of decreasing hormone levels have come to the forefront as a quality-of-life issue for patients and their families. For the past two decades, the healthcare industry has responded to this clinical need by developing, testing and marketing hormone replacement therapy (HRT) products. Because of their ease-of-use and dosing characteristics, drug developers

Self-Monitoring for Hypertension Patients Growing as Technology and Devices Impr …

(Amherst, NH) – The ability of patients to self-monitor is deemed to be a critical tool in reducing the healthcare effects of chronic disease factors. The convergence of new measurement technologies, patient demographics and managed care cost initiatives is driving patient monitoring for a number of conditions from caregiver facilities and into homes. The key enablers of this significant shift are technological advances that provide accurate readings in a format

As Variable Dosing for Injectable Drugs Increases, Devices Strive to Keep Pace

(Amherst, NH) - The growing number of injectable drugs that requiring dosing based on metabolic readings or patient-specific treatment protocols is driving the growth of injection devices that allow the patient or caregiver to set the drug dose and vary the dose over time. Because earlier generations of specialty drug injectors were initially introduced for the administration of insulin by diabetics, it is not surprising that variable dose pens

Technology Gains Renewing Interest in Needle Arrays as Drug Delivery Devices

(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs designed to be delivered across the skin, needle arrays are viewed as an approach that addresses these

Drug Delivery Pen Injectors Growing by Providing Key Benefits to Both Suppliers …

(Amherst, NH) – As the underlying structure of their markets continues to change, injectable drug developers are refining their product models to reflect the economics and demographics of primary target indications. Gone are the days when vials were the only packaging option and insulin-dependent diabetes was the only significant self-treatment or home care condition. A number of factors have converged to create challenges and opportunities for injectable drug suppliers and

Insulin Patch Pumps Proliferating, Creating New Options for Controlling Diabetes

(Amherst, NH) – Taken together the two classifications, or types, of diabetes are among the most expansive and expensive chronic conditions currently facing the healthcare community. Recent predictions and forecasts are projecting that the market for insulin will grow significantly in the next five years as the number of patients diagnosed with either Type I or Type II diabetes grows dramatically worldwide. The human and financial incentives of this trend

Projected Growth of Diabetes Patient Population Driving the Appearance of Numero …

(Amherst, NH) – The expected surge in the incidence of diabetes is creating a health care conundrum for public health officials and a potential business opportunity for market sector participants. The issue of glycemic control and its correlation with patient morbidity and mortality has fueled awareness of the need for improved patient compliance with glucose monitoring. The convergence of these forces is creating the perception of a once-in-a-decade opportunity for

Inhaled Antibiotics and Antivirals Creating Treatment Options for Caregivers and …

(Amherst, NH) – Advances in drug formulation and inhalation device design are creating new opportunities for inhaled antibiotics and antivirals for the treatment of chronic as well as acute infections and secondary conditions. The interest in inhaled administration of antimicrobials is based in large part on their ability to provide rapid onset of action at the site of infection or inflammation. Because they are indicated for patients who are often

Extended Release Drugs for Neurology Providing Caregivers and their Patients wit …

(Amherst, NH) – In terms of dosing regimens and patient compliance, neurological disorders represent one of the most challenging areas of therapeutic medicine. Patients diagnosed with conditions such as schizophrenia, Alzheimer’s disease, Parkinson’s disease, and manic depressive disorder are often not physically and/or mentally capable of reliably following dosing instructions for the medications that they’ve been prescribed. The availability of approved drugs for neurological disorders with extended release

Demographics and Improving Technology to Provide Coagulation Self-Testing with P …

(Amherst, NH) – The ability of patients to monitor their own serum levels is deemed to be a critical tool in reducing the pathological effects of difficult-to-control disease factors. For the millions of patients in the US and worldwide prescribed warfarin for oral anticoagulation therapy (OAT), the ability to monitor coagulation rates and adjust drug dosage to optimize therapeutic outcomes is a critical element of patient care. The availability of

Demographics of Several CNS Indications Position Transdermal Drugs for Growth

(Amherst, NH) – Despite recent progress in a number of therapeutic sectors, progress toward curative medicine for neurological and related central nervous system disorders has remained elusive. The result is a therapeutic sector that relies heavily on control of symptoms and palliative care. This disappointing picture is being exacerbated by disease trends that are increasing the morbidity and mortality associated with CNS ailments in the general population. These trends include

Patient Self-Monitoring Positioned for Growth

(Amherst, NH) – Current efforts to reduce the societal impact of chronic ailments such as diabetes and heart disease are focused on several factors, including the identification of genetic and environmental risk factors, patient education, and improved patient compliance. The ability of patients to monitor their own blood analyte levels is deemed to be a critical tool in reducing the pathological effects of poorly controlled disease factors. The convergence of

Advantages of Administering Pain Drugs via Inhalation Go Beyond Convenience

(Amherst, NH) – The challenges of delivering drugs for treating pain – particularly in compromised patients - are well-documented. To address the risk and compliance factors associated with the administration of pain drugs, developers and researchers have been investigating inhalation – intranasal as well as oral inhalation – as a way to mitigate several of these issues. The market for inhaled pain drugs is currently dominated by products designed for

Transmucosal Drug Delivery Gaining Interest in Niche Markets

(Amherst, NH) – In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery, which includes buccal tablets and films, oral spray and sublingual films and wafers, offers the potential for once daily dosing of oral drugs and avoids

New-Generation Transdermal Drug Patches Relying on Technology Convergence to Ach …

(Amherst, NH) – The therapeutic window open to transdermal drug patches has traditionally been defined by skin permeability and dose rate issues related to the limitations of passive drug diffusion through the stratum corneum. Formulation efforts and the use of excipients to improve drug migration have yielded only modest improvements. The result has been a drug delivery technology that has been confined to a handful of therapeutic markets dominated by

Microneedle Drug Delivery Systems Moving Toward Commercialization by Converging …

(Amherst, NH) – For the past decade a small group of device development companies, often supported by academic partners and national government technology transfer programs, have been attempting to commercialize drug delivery products based on arrays of microneedles. By creating channels in the stratum corneum, these devices were expected to deliver therapeutic drugs across the skin and into the dermal layers. While several product efforts focused on achieving a local

Share of Injectables Supplied in Drug Cartridges Continues to Increase

(Amherst, NH) – In the past two decades, drug delivery has become a major factor in the advancement of the quality of life and a key factor in the business success of pharmaceutical companies. During this time, syringes and injectors have evolved considerably to address the changing demands of clinicians and their patients. In particular, the appearance and refinement of disposable drug cartridges has created unique opportunities for developers of

Prefilled Syringes to Reach 4.35 Billion Units in 2015 According to Greystone Re …

(Amherst, NH) – Driven by improved device designs, a maturing supply chain infrastructure and broad acceptance of inherent patient and caregiver benefits, prefilled syringes will continue to grow at a double digit rate, climbing past four billion units worldwide in 2015, according to the latest estimates from Greystone Research Associates. “Prefilled syringes continue to grow because they address factors that represent fundamental goals within the healthcare sector,” explains George Perros,

Active Transdermal Delivery Growth Being Driven by Technology Convergence

(Amherst, NH) – As the pharmaceutical industry struggles to deal with the impact of low-cost generics, consolidations and workforce reductions, drug technologists are continuing to work on the development of drug therapy technology that eliminates or minimizes the role of the patient in the medication process. These programs are being driven by the double-digit growth in self-administration being propelled by the emphasis on healthcare cost containment, and the ongoing issue

Growth of Needle-free Injection Hinges on Penetrating Niche Markets

Amherst, N.H. – Long considered a novel technology with limited practical value, needle-free injection (NFI) is attempting to shed its image as an out-of-the-mainstream drug delivery technique. The convergence of improved device designs, patient sentiment and new therapeutic applications is re-making NFI into an attractive technology being pursued by a number of major pharmaceutical companies. As interest in NFI increases, collaborations and acquisitions between leading NFI companies and drug developers are

Drug Delivery Coatings Creating Opportunities for Developers and Practitioners

(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering APIs. These participants are exploring a

Dry Powder Inhalation Expanding in Established Markets while Pursuing New Therap …

(Amherst, NH) – Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. While several approaches for delivering active substances via oral inhalation compete in this space, dry powder inhalation (DPI) continues to attract investment in new combination product development and therapeutic indications at the expense of more established methods such as metered dose inhalers

Drug Solubilization Technologies Creating Options for Developers

(Amherst, NH) – More than ever before, drug formulation technology is now seen as a key enabler of new prescription products. Much of the current focus in formulation science is concerned with processes that can improve the solubility of APIs. Solubility remains one of the most common reasons given for dropping a drug from development. The importance of solubilization technologies is also underscored by the capability they bestow on

Autoinjectors Creating Opportunities for Drug Marketers

(Amherst, NH) – The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives. For drugs developed for self-administration and available in prefilled syringes, autoinjectors have been shown to provide a more user-friendly outer package and improved compliance. While

Point-of-Delivery Drug Reconstitution Systems Growing by Simplifying the Safe Ad …

(Amherst, NH) – Supplying drugs that must be administered as a liquid in solid form has been used to improve drug stability since early in the last century. Lyophilized drugs for injection are typically sold in vials packaged with a diluent syringe, but a growing number are including reconstitution vial systems that incorporate a vial adapter or vial transfer device. Dual chamber drug cartridges and syringes go a step further

Go To Page:    1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0